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Abstract
Estrogens play a pivotal role in the development and progression of prostate cancer (PCa). Their
actionsaremediatedbyestrogenreceptors(ERs),particularlyERbintheprostateepithelium.Withthe
discovery of ERb isoforms, data from previous studies that focused principally on the wild-type ERb
(ERb1) may not be adequate in explaining the still controversial role of ERb(s) in prostate
carcinogenesis. In this study, using newly generated isoform-speciﬁc antibodies, immuno-
histochemistry (IHC) was performed on a tumor microarray comprised of 144 specimens. IHC results
were correlated with pathological and clinical follow-up data to delineate the distinct roles of ERb1,
ERb2, and ERb5i nP C a .E R b2 was commonly found in the cytoplasm and was the most abundant
isoformfollowedbyERb1localizedpredominantlyinthenucleus,andERb5wasprimarilylocatedinthe
cytoplasm. Logistic regression analyses demonstrated that nuclear ERb2( n E R b2) is an independent
prognosticmarkerforprostatespeciﬁcantigen(PSA)failureandpostoperativemetastasis(POM).Ina
Kaplan–Meier analysis, the combined expression of both nERb2 and cytoplasmic ERb5 identiﬁed a
group of patients with the shortest POM-free survival. Cox proportional hazard models revealed that
nERb2 predicted shorter time to POM. In concordance with IHC data, stable, ectopic expression of
ERb2o rE R b5 enhanced PCa cell invasiveness but only PCa cells expressing ERb5 exhibited
augmented cell migration. This is the ﬁrst study to uncover a metastasis-promoting role of ERb2a n d
ERb5inPCa,andshowthatthetwoisoforms,singularlyandconjointly,haveprognosticvaluesforPCa
progression. These ﬁndings may aid future clinical management of PCa.
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Introduction
Prostate cancer (PCa) is the most common cancer
and the second leading cause of death among
American men (Jemal et al. 2009). Although androgen
deprivation therapies (ADTs) remain as the mainstay
treatment for advanced PCas, these therapies
eventually fail, in part, due to the development
of androgen hypersensitivity, ligand-independent
androgen receptor (AR) transactivation, and AR gene
mutations and/or ampliﬁcation in PCas (Scher et al.
2004, Culig & Bartsch 2006). The recently discovered
AR spliced variants in PCa further raise concerns on
the efﬁcacy of these therapies (Dehm et al. 2008, Guo
et al. 2009). Thus, limitations revolving around ADTs
have prompted exploration of other therapeutic
options. Transdermal estrogen patches as a ﬁrst-line
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PCa (Langley et al. 2008) are now in phase II trials.
However, despite signiﬁcant research efforts, the
role(s) of estrogen in the pathogenesis of PCa remains
poorly understood.
The incidence of PCa rises dramatically in men older
than 55. This phenomenon could be due to hormonal
changes during aging. Among older men, androgen
levels drop signiﬁcantly, whereas their estrogen levels
remain unchanged or increased, making the estrogen to
androgen ratio elevated in the aging prostate (Ho et al.
2006). Epidemiological studies indicate a correlation
between PCa and circulating estrogen levels, but not
circulating testosterone levels, among different ethnic/
racial groups with diverse PCa incidence (Rohrmann
et al. 2007). In addition, estrogen is produced locally
by aromatase, which converts androgen into estrogen
in the prostate (Stone et al. 1986, Matzkin & Soloway
1992, Ellem et al. 2004, Takase et al. 2006). Estrogens
are essential in supporting the normal functioning of
the prostate, and yet have long been suspected as a risk
factor for PCa. Long-term exposure to elevated levels
of estrogen against a normal androgen background
induced a high incidence of PCa in rodents (Leav et al.
1988, Prins et al. 2007, Ricke et al. 2008). Also, in
utero exposure to higher levels of maternal estrogen in
African–American men may be associated with higher
PCa risk (Henderson et al. 1988), a thesis supported by
animal studies (Prins 1997, Ho et al. 2006, Prins &
Korach 2008).
Estrogen receptors (ER), ERa and ERb, are the
major mediators of estrogen signaling. Upon binding
of estradiol-17b, ER in the nucleus forms a homo-
/heterodimer and binds either directly to the classical
estrogen-responsive element (ERE) or indirectly to an
NFkB-, Ap1-, or Sp1-binding element via tethering
with their respective transcription factors, thereby
initiating downstream signaling cascades (Heldring
et al. 2007). The roles of ERs in the prostate are not
fully understood. ERa is found primarily in stromal
cells of the prostate, and appears to regulate the growth
and differentiation of prostatic epithelial cells in a
paracrine fashion (Ellem & Risbridger 2009). In the
prostatic epithelium, ERb is the predominant ER
subtype (Kuiper et al. 1996), but its function remains
controversial. Hyperplasia and dysplasia have been
found in the prostates of adult ERb knockout mice
(Krege et al. 1998, Weihua et al. 2001), arguing for an
antiproliferative role of ERb (Morani et al. 2008).
However, other research groups did not observe such
phenotypes in their ERb knockout mice (Couse et al.
2000, Dupont et al. 2000, Antal et al. 2008). We and
others have shown that the expression of ERb in human
prostate epithelial cells decreases as PCa develops and
progresses to a higher grade (Leav et al. 2001, Zhu
et al. 2004), but reappears in the lymph node and bone
metastases (Lai et al. 2004, Zhu et al. 2004). The
dynamic change in ERb expression is epigenetically
regulated by reversible cytosine methylation of an AP2
site in a CpG island located in the ERb proximal
promoter (Zhu et al. 2004, Zhang et al. 2007). These
ﬁndings suggest that ERb may play a protective role
during early stages of prostate carcinogenesis, but
either promote metastasis or support PCa cell survival
at distant sites (Leav et al. 2001). Apropos to the
postulate that ERb promotes PCa metastasis, a few
reports have demonstrated an association between ERb
immunopositivity in high-grade PCa and poor relapse-
free survival time (Horvath et al.2 0 0 1 , Nanni et al.
2009). However, further delineation of the role of ERb
(s) in PCa progression is needed.
The continuing controversy over the function of
ERbs in prostate carcinogenesis could be due to
variable expression levels of different ERb isoforms
in benign versus malignant tissues during different
stages of the process. In humans, in addition to the
wild-type ERb or ERb1, four spliced variants
designated as ERb2–5 have been identiﬁed (Moore
et al. 1998). The ERb2–5 isoforms share the ﬁrst four
functional domains with ERb1, but each has a unique
activation function 2 (AF2) domain. Since isoform-
speciﬁc antibodies were unavailable until very
recently, the use of various antibodies directed against
different domains of the molecules might have
generated immunohistochemistry (IHC) patterns that
contradict each other.
No functions for ERb2–5 isoforms in the prostate
have yet been identiﬁed except in one study with 48
cases, suggesting that ERb2 may be a poor prognostic
marker for PCa (Fujimura et al. 2001). A breast cancer
study, however, has implicated nuclear ERb2 (nERb2)
and nuclear ERb5 (nERb5) to predict better prognosis
(Shaaban et al. 2008). To clarify the role of ERb1 and
its isoforms ERb2 and ERb5 in PCa, we evaluated the
expression patterns of these three ERbs in a set of
tissue microarrays (TMAs) from a cohort of 144
patients with long follow-up using newly developed
in-house isoform-speciﬁc antibodies. We found that
nuclear expression of ERb2 in PCa was an independent
prognostic marker for prostate speciﬁc antigen (PSA)
failure (PF), postoperative metastasis (POM), and time
to POM. Furthermore, the coexpression of nERb2 and
cytoplasmic ERb5 (cERb5) was found associated with
the worst prognosis in terms of POM-free survival
time. We have further demonstrated that the stable,
ectopic expression of ERb5 in PCa cells increased cell
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growth, while the expression of ERb2 augmented
only cell invasion. In aggregate, our data suggest that
ERb isoforms have variable functions and prognostic
values in PCa.
Materials and methods
Patient population
With Institutional Review Board (IRB) approval, we
included 144 patients with PCa who underwent radical
prostatectomy at the Massachusetts General Hospital
(Boston, MA, USA) from September 1993 to March
1995 in this study. All hematoxyolin–eosin (H&E)-
stained sections from each case were reviewed, and
the Gleason score was reassigned on the basis of the
current grading recommendation provided by the
International Society of Urological Pathology (Epstein
et al. 2005). The tissue blocks containing the index
PCa (tumor focus with the highest Gleason score) were
selected for inclusion in the TMA. The relevant
clinicopathological data collected included age; pre-
operative PSA; Gleason score; American Joint
Committee on Cancer (AJCC) T stage; surgical
margin; and POM, follow-up of PSA recurrence, and
overall survival. PF was any detectable PSA after PSA
nadir post-surgery. The value was 0.5 ng/ml before
1999 and 0.2 ng/ml since 1999. POM comprised bone
and lymph node metastases.
TMA construction
The TMAs were constructed using a manual tissue
array instrument (Beecher Instruments, Silver Spring,
MD, USA). Brieﬂy, the H&E-stained slides were
reviewed for accuracy of Gleason scores and for the
availability of adequate areas of each component
Gleason grade pattern; the index tumor, deﬁned as
the largest and/or highest Gleason score, was identiﬁed
on the slide; and the representative highest Gleason
score areas were marked. Three tissue cylinders with a
diameter of 0.6 mm were punched from selected areas
of each donor block and brought into a recipient
parafﬁn block. Each block contained normal prostate
tissue derived from normal peripheral zone away from
the tumor and benign prostatic hyperplasia. The normal
tissue serves as an internal control and a reference of
staining intensity for adjacent cancer foci. After
construction of the TMA blocks, H&E-stained sections
were made for histological evaluation.
Antibodies
ERb1-speciﬁc antibody (GC-17, Biogenex, San
Ramon, CA, USA) recognizing amino acid residue
502–518 of the AF2 domain was developed in our
laboratory, and shown to be highly speciﬁc in both
western blot and IHC assays (Leav et al. 2001).
Polyclonal monospeciﬁc antibodies speciﬁc for
C-terminal peptides within ERb2 (482-MKMETLL-
PEATMEQ-495) and ERb5 (459-LMLLSHVRHAR-
YAP-472) were prepared by immunizing rabbits with
the targeted peptide conjugated to BSA according to
the afﬁnity-puriﬁed package offered by New England
Peptide (Gardner, MA, USA). Because we found
puriﬁed IgGs of ERb2 and ERb5 to be unstable, we
used antisera for all subsequent analyses. The
expression of all isoforms in western analyses was
conﬁrmed with an N-terminal-speciﬁc antibody (H150,
Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Western blot analyses
To evaluate the speciﬁcity of our ERb2 and ERb5
antisera, we expressed various ERb isoforms (ERb1,
ERb2, and ERb5) in HEK293 cells and used these as
reagents for testing the speciﬁcity of an antiserum.
Methods for cell culture maintenance, DNA transfec-
tion, and western blot analyses were similar to those
previously reported (Leung et al. 2006). The dilution
ratio for the primary antibodies used in this study was
maintained at 1:1000.
IHC analyses
The detection of ERb1, ERb2, or ERb5e x p r e s s i o no n
human prostate parafﬁn-embedded sections was carried
outaccordingtoourpublishedprotocolsforERb1(Leav
et al.2 0 0 1 ). The optimal dilution ratio for each primary
antiserum was determined empirically, and found to be
1:100 for ERb1a n dE R b5 and 1:500 for ERb2. These
dilution ratios were used throughout our study. The
speciﬁcity of ERb2a n dE R b5 antisera was determined
by neutralizing each antiserum with a 10! excess (by
weight) of its respective targeted peptide. Peptides
derived from ERb1 (GCKSSITGSECSPAEDS), ERb3
(CSWRLFMLREAS), ERb4 (CVRHARWGEKQ-
FIHLK), and ERb5 (CSHVRHARYAP) were also
applied to the IHC studies to further evaluate the
antibody speciﬁcity. The antibody–peptide precipitate
was removed by centrifugation at 12 000 g for 10 min
after overnight incubation at 4 8C. The supernatant (pre-
absorbed serum) was used in parallel with the primary
antiserum asa negative control toestablishspeciﬁcityof
its respective antiserum.
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the same IHC protocol. IHC results were scored,
evaluated, and graded independently in a blinded
fashion by two investigators (C-L W and S W),
including one experienced urological pathologist (C-L W).
Nuclear and cytoplasmic signals of each ERb
isoform were examined separately. Signal intensity
and percentage of signal coverage of each region were
scored according to the Allred scoring system (Allred
et al. 1993). The intensity signal was graded from 0 to
3 (0, none; 1, weak; 2, intermediate; 3, strong), and
the percentage of positive tumor cells was scored from
1 to 5 (1, !1%; 2, 1–10%, 3, 10–30%; 4, 30–60%;
5, O60%). For example, if the same specimen was not
stained by either of the antibodies, it will be scored as
0C1 (Allred score (Ascore)Z1, i.e. negative).
Subcellular localization studies
PC3 cells (ATCC, Manassas, VA, USA) were
maintained under standard conditions and cultured on
coverslips. A full-length sequence of ERb isoforms 1,
2, and 5 was subcloned into pEF-yellow ﬂuorescent
protein (YFP)-C1 (Clontech) and expressed as a fusion
protein with an N-terminal YFP tag in PC3 cancer cells
following the Lipofectamine 2000 (Invitrogen) trans-
fection protocol. At 48 h after transfection, cells were
incubated with 250 nM Mito-tracker Red CM-H2XRos
(Invitrogen) for 45 min and ﬁxed with 4%
formaldehyde for 15 min. Cells were then permeabilized
with 0.2% Triton X-100 before their nuclei were
counterstained with 300 nM 40,6-diamidino-2-pheny-
lindole (DAPI) (Invitrogen) and preserved in Prolong
Antifade Gold reagent (Invitrogen). Fluorescent
signals were captured and evaluated with an Axiovert
200M ﬂuorescent microscope equipped with an
AxioCam MRm camera and Axiovision 4.7 software
(Carl Zeiss, Thornwood, NY, USA). Optical sections
were generated using ApoTome (Carl Zeiss).
Construction of PC3 cells stably expressing
ERb isoforms
Full-length sequences of ERb1, ERb2, and ERb5 were
subcloned into a pLenti6 lentiviral vector recombined
with an ubiquitin promoter by Multisite Gateway
recombination reactions (Invitrogen) and transfected
into 293FT cells for production of lentivirus according
to the manufacturer’s protocol. Lentivirus carrying the
LacZ gene was used as a control. The use of the
ubiquitin promoter, which is a constitutive but
relatively weak promoter, minimized artifacts intro-
duced by other virus-based promoters. The titer of each
lentivirus was measured, and the multiplicity of
infection of PC3 cells was 0.7. Lentivirus-infected
PC3 cells were cultured in medium supplemented with
blasticidin at 8 mg/ml and selected for 3 weeks. PC3
cells stably expressing LacZ, ERb1, ERb2, and
ERb5 were designated as PC3–LacZ, PC3–ERb1,
PC3–ERb2, and PC3–ERb5 respectively. Expression
of the transgenes was conﬁrmed by real-time
PCR assays.
Cell migration and invasion assays
Cellular mobility of PC3–LacZ, PC3–ERb1,
PC3–ERb2, and PC3–ERb5 cells was evaluated with
a wound-healing assay (Rodriguez et al. 2005), and
their invasiveness through the extracellular matrix was
determined by the BD BioCoat Matrigel Invasion
Chamber method (BD Biosciences, San Jose, CA,
USA) following the manufacturer’s protocol.
Statistical analysis
Descriptive statistics were calculated for demographic
and clinical measures. Preliminary associations
between Ascores measuring the expression level of
cytoplasmic and nERb1, 2, and 5 were analyzed using
Mantel–Haenszel c
2 test statistics to evaluate associ-
ations with PF and POM. A signiﬁcant relationship
with at least one outcome was found for one isoform of
each type (P!0.05). These Ascores were included in
logistic regression analyses, adjusted for Gleason score
and age. Ascores were dichotomized at cutpoints
where slopes of Ascores changed, determined by
statistical evaluations of curves ﬁtted to the data, and
visual assessment. Two cutpoints were chosen for each
outcome and each Ascore. The best model was chosen
by evaluating goodness-of-ﬁt statistics. Cox pro-
portional hazard models were used to analyze time to
PF and time to POM. Kaplan–Meier plots of PF and
POM survival were analyzed, stratiﬁed by dichoto-
mized cytoplasmic and nuclear levels. An a-level of
0.05 was used to determine signiﬁcance, unless
otherwise stated. Analyses were performed with SAS
for Windows, Version 9.1.2 (SAS Institute, Cary, NC,
USA) and GraphPadPrism4 (La Jolla, CA, USA).
Results
Evaluation of ERb2 and ERb5 antisera for
isoform speciﬁcity
A speciﬁc antibody targeting each isoform is
necessary for studying the expression of ERb isoforms.
An ERb1-speciﬁc antibody (GC17) that we had
raised previously has been widely used in PCa research
(Leav et al. 2001, Adams et al. 2002, Pais et al. 2003,
Y-K Leung et al.: ERb isoforms and prostate cancer progression
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polyclonal monospeciﬁc antisera to ERb2 and ERb5
based on isoform-speciﬁc C-terminal sequences. We
ﬁrst overexpressed full-length ERb1, 2, 3, 4, or 5
expression plasmids (Leung et al.2 0 0 6 ) in HEK293
cells and used the cell lysates to test the speciﬁcity of
ERb2 and ERb5 antiserum by western blot analysis.
We used a pan-ERb antibody to conﬁrm the expression
of each ERb isoform protein in HEK293 cells
(Fig. 1A). We then reblotted the same lysates with
ERb2-speciﬁc (Fig. 1B) or ERb5-speciﬁc (Fig. 1C)
antiserum. ERb2-speciﬁc antiserum recognized a
single 56-kDa band in lane 3, which was loaded with
a lysate from HEK293 cells expressing the ERb2
transgene. No cross-reactivity with other isoforms
(lanes 2, 4, 5, and 6) was detected in this ERb2
western blot. Similarly, the ERb5 antiserum strongly
recognized a 53-kDa band in lane 6 that was
loaded with a lysate from HEK293 cells harboring
the ERb5 transgene.
We then investigated whether we could use the new
antisera for IHC. To validate the speciﬁcity of an
antiserum, we immunostained serial prostate archival
sections with or without ERb isoform-speciﬁc
peptides. At low magniﬁcation (!100), the ERb2
antiserum primarily stained the cytoplasm of the basal
and luminal epithelial cells of benign glands (Fig. 1D)
and also stained the nuclei of some stromal cells. The
immunopositive signals were not blocked by other
ERb isoform-speciﬁc peptides (Fig. 1E, G, H, and I)
but totally abolished by the ERb2 peptide (Fig. 1F).
These results showed that the speciﬁcity of ERb2
antiserum for ERb2 was excellent. Similarly, ERb5
antibody strongly stained the cytoplasm of basal
epithelial cells but not the luminal epithelial cells
(!100) and weakly stained some stromal cells
1
56 kDa
DE
FG
HI
JK
LM
NO
AB C
52 kDa
M234 5 6
ERβ pan
12 M3 4 5 6 1 2 M3 4 5 6
ERβ2E R β5
Figure 1 Speciﬁcity of ERb isoform-speciﬁc antibodies.
Western blot analyses: HEK293 cells expressing ERb1–5
lysate were tested against ERb pan antibody ((A) Santa Cruz
H150), ERb2-speciﬁc antibody (B), and ERb5-speciﬁc antibody
(C). Lane 1 was loaded with control cell lysate (HEK293 cells
only), whereas lanes 2–6 were loaded with HEK293 cell lysate
expressing ERb1–5 respectively. M stands for protein marker
(Invitrogen SeeBlue Plus2 protein ladder). The expected
protein band of the ERb isoforms 2 and 5 was labeled by
an arrow in the middle and right panel respectively.
Immunohistochemical (IHC) analyses: IHC analyses of benign
prostatic tissue were carried out using ERb2- (D–I) and
b5-speciﬁc antisera (J–O). ERb1-, ERb2-, ERb3-, ERb4-, and
ERb5-speciﬁc peptides were applied to the IHC analyses.
Figures showing IHC analyses with or without ERb isoform-
speciﬁc peptide are arranged as follow: D and J (no peptide);
E and K (CERb1 peptide); F and L (CERb2 peptide); G and M
(CERb3 peptide); H and N (CERb4 peptide); I and O
(CERb5 peptide).
Endocrine-Related Cancer (2010) 17 675–689
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were totally eliminated by its blocking peptide
(Fig. 1O) but not by other isoform-speciﬁc peptides
(Fig. 1K, L, M, and N), verifying the speciﬁcity of
ERb5 antiserum for IHC analyses.
Immunocytochemistry analyses of ERb isoforms
in PCa specimens
Although we showed the antisera to be speciﬁc to their
respective antigen, we also found that they may
crossreact with other ERb isoforms. We therefore
further examined our ERb-stained sections at high
magniﬁcation (!630) to determine whether the
staining pattern was unique for each antibody/anti-
serum. Immunostained benign glands (Fig. 2A–F) and
cancer foci, consisting of Gleason grade 3 cancer
glands (Fig. 2G–M), were compared in parallel. In
benign prostate glands, ERb1 was localized principally
in the nuclei of basal epithelial cells (Fig. 2A and D) as
previously reported for GC17 staining (Leav et al.
2001). ERb1 was also localized in the nuclei of a few
luminal epithelial cells but was found quite frequently
in the perinuclear zone in luminal epithelial cells. The
nuclei of some stromal cells were also strongly stained
by the ERb1 antibody (GC17). In contrast, the ERb2
was localized predominantly to the cytoplasm of both
basal and luminal epithelial cells, with clear local-
ization in the supranuclear zone of the luminal cells
(Fig. 2B and E); nuclear localization was uncommon.
ERb5, however, was localized almost exclusively
in basal epithelial cells in benign prostate glands
(Fig. 2C and F); intracellular localization was primarily
cytoplasmic. In PCa, such as in Gleason score 6 (3C3)
cancer foci (Fig. 2K), some foci of ERb1 positivity
were lost in both nuclear and cytoplasmic compart-
ments, but some remained (Fig. 2J). ERb2( Fig. 2H
and L) and ERb5( Fig. 2I and M), however, displayed
a diffused pattern of cytoplasmic staining, with
occasional nuclear positivity. In summary, the three
antibodies/antirsera produced distinct staining patterns
in both benign glands and cancerous prostatic foci,
thereby providing support for the suggestion that each
of them is highly speciﬁc and probably recognizes only
one ERb isoform in IHC studies.
Subcellular localization of ERb isoforms
in PCa cells
To elucidate the subcellular localization of ERb
isoforms in PCa cells, we ectopically expressed ERb1,
ERb2,orERb5inPC3cellsintheformofanYFPfusion
protein, with YFP serving as a control (Fig. 3A–D).
YFP–ERb1 was found principally in the nucleus, with
very weak signals in the cytoplasm (Fig. 3E). The
cytoplasmic signal did not overlap the Mito-tracker red
signal(Fig.3G),suggestingthatERb1doesnotresidein
mitochondria in PC3 cells. Similarly, the YFP signal of
ERb2( Fig. 3I) and ERb5( Fig. 3M) was found in both
the nuclei and cytoplasm of the PC3 cells, and no
overlappingsignalwiththeMito-trackerredsignalswas
detected in both cases (Fig. 3K and O). Of interest was
the stronger cytoplasmic signal of YFP–ERb5 among
the ERb isoforms.
ERβ1E R β2E R β5E R β1
J KL M F E D 20 µm 20 µm 20 µm 20 µm 20 µm 20 µm
Grade score 6
ERβ2E R β5
ABC GH I J
K
Normal
Figure 2 Immunohistochemical analyses of ERb isoforms in benign prostate glands (A–F) and prostate adenocarcinoma in
PCa specimen (G–M). PCa specimens from cancers with Gleason score 6 (G–M) and its adjacent normal region (A–F) were
immunostained with ERb1-, ERb2- and ERb5-speciﬁc antibodies/antisera. See Materials and methods for the experimental
conditions. Figures D–F and J–M are the magniﬁed view (!630) of a region (marked by a rectangle) in Figure A–C and G–I (!100)
respectively. InERb1immunostaining,positivesignalswerefoundmostlyinthenucleiofbasalepithelialcellsinbenignfoci(AandD)
andinthenucleiofPCacells(GandJ)despitesparsenuclearstaininginstromalcells(indicatedbylightbluearrowheadsinﬁguresD
and J). ERb1 staining was lost in some PCa foci (K). ERb2 staining is highly cytoplasmic in both benign (basal and luminal epithelial
cells,B andE) andPCafoci(H and L).ImmunopositivesignalsofERb5 wereobservedinthe cytoplasmicregionof theepithelialcells
in adjacent normal foci (C and F) as well as in PCa cells in Gleason score 6 cancer (I and M).
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were used to construct the TMA
The majority of the patients (nZ133) were Caucasian–
Americans (92.4%; Table 1). Only 11 were non-
Caucasian: African–American (3.5%), Hispanic
(2.8%), or Asian (1.4%). Ages ranged from 46 to 77
years (meanZ62). Approximately 44% of the patients
had low-grade cancer (Gleason score !7), 40%
had intermediate-grade PCa (Gleason score Z7),
and 16% had higher-grade cancer (Gleason score O7).
The postoperative PSA levels of patients were
measured for an average of 6.2 years. PF was detected
in 37.5% of the patients (nZ54). POM was found in
8.3% of the patients (nZ12). The average time to PF
and POM was 6.2 and 8.6 years respectively.
TMA analyses
To elucidate the clinical relevance of the expression of
ERb1, ERb2, and ERb5 in PCa, we used our newly
validated antisera and ERb1-speciﬁc antibody (GC17)
in an IHC analysis of a set of TMAs comprising 144
specimens with a well-documented clinical history.
Figure 4 shows typical results of IHC staining with
ERb1, 2, or 5 antibody/antisera. Typical TMA sections
showing low to moderate staining of ERb isoforms are
shown in Fig. 4A, D, and G. In a few rare instances,
both nuclear and cytoplasmic staining of ERb isoforms
was observed in some of the TMA sections (Fig. 4B, E,
and H). With higher magniﬁcation (!630), nuclei in
PCa cells were differentially stained by the isoforms –
antibody/antisera (Fig. 4C, F, and I). We noted
different staining patterns in some specimens of similar
cancer grade even with the same antibody/antiserum
and IHC conditions. Variations were greater in the
specimens positive for ERb1 and ERb5. The pattern
for ERb2 was less variable.
Distinct subcellular localization patterns of ERb
isoforms in PCa specimens
ERb1, 2, and 5 showed distinctly different expression
patterns in this set of PCa TMAs. ERb2 was found to
be the dominant ERb isoform in PCa (Fig. 5). Over
80% of the samples (nZ127) showed a positive ERb2
signal. Most of the ERb2( nZ108) was localized in the
cytoplasm of the PCa cells, but w10% resided in the
nucleus. ERb1 was the second most common
isoform in this set of TMAs. Since 84% of the patients
(nZ121) had intermediate-grade PCa (Gleason 5–7) at
prostatectomy, in agreement with previous studies,
most of their prostate specimens still retained ERb1
staining (Fig. 2; Leav et al. 2001). In contrast to the
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benign glands, ERb1 was found more often in both
the nuclear and cytoplasmic compartments or in only
the cytoplasmic compartment of PCa cells. ERb5 is the
least common isoform; only 36% of patients (nZ52)
showed ERb5 positivity, which was predominantly
expressed in the cytoplasm of the cancer cells (O90%
of the cases, nZ49).
Since we had previously shown that the various
ERb isoforms formed heterodimers with ERb1i n
cell culture under different conditions of ligand
stimulation (Leung et al. 2006), we calculated
Spearman correlation analyses to determine the
possibility of ﬁnding two of the three ERbs in the
same cellular compartment in the PCa specimens
(Table 2). Despite low-to-moderate correlations, a
signiﬁcant difference from zero was found for the
correlation between ERb1 and ERb2 in the nucleus
(rZ0.45) and the cytoplasm (rZ0.39; P!0.01),
suggesting that ERb1 and ERb2 may be coexpressed
in the nuclei or cytoplasm of PCa cells. ERb5, which
is predominantly cytoplasmic, therefore showed a
better correlation only with cERb1( rZ0.37) and
cERb2( rZ0.26; P!0.01), implying that some
specimens may coexpress ERb5 with at least one
other ERb.
Statistical results of TMA studies
nERb2 and cERb5 Ascores were signiﬁcantly related
to PF and/or POM. Ascores were dichotomized as
negative (%3) and positive (O3) based on statistical
assessment and results of a previously published study
(Shaaban et al. 2008). Descriptive statistics evaluating
differences betweendichotomized Ascores and clinico-
pathological features of PCa showed that age,
preoperative PSA, and Gleason score were signiﬁ-
cantly different (P!0.10) for at least one isoform
(nERb2 and cERb5; Table 3). Positive expression of
nERb2 was signiﬁcantly associated with PF (adjusted
odds ratio (adjOR)Z3.8, PZ0.04) and POM
(adjORZ3.1, PZ0.02), while cERb5 positivity did
not show a signiﬁcant association with either PF
(adjORZ0.8, PZ0 . 5 8 )o rP O M( a d j O R Z3.1,
PZ0.09; Table 3). Signiﬁcantly poorer survival (time
to POM), independent of Gleason score, age, and
preoperative PSA, was associated with nERb2 posi-
tivity (adjusted hazard ratio adjHRZ4.6, PZ0.02).
These results suggest that nERb2 is an independent
prognostic marker for predicting time to POM. Time to
PF was not signiﬁcantly associated with positivity of
nERb2 or cERb5( PO0.05). Kaplan–Meier plots and
the log-rank test statistics showed that time to PF and
time to POM were signiﬁcantly shorter for patients
with nERb2 positivity (P!0.01; Fig. 6A and B).
cERb5 positivity, on the other hand, was signiﬁcantly
Table 1 Characteristics of 144 patients
Variables n (% total patients)
Age (years)
46–50 4 (2.8)
50–59 49 (34.0)
60–69 81 (56.3)
70–77 10 (6.9)
Race
Caucasian–American 133 (92.4)
African–American 5 (3.5)
Hispanics 4 (2.8)
Asian 2 (1.4)
Pathology stage
T2 115 (79.9)
T3 29 (20.1)
Gleason score
!7 63 (43.8)
Z7 58 (40.2)
O7 23 (16.0)
Surgical margin
Positive 58 (40.3)
Negative 86 (59.7)
PSA failure
Yes 54 (37.5)
No 90 (62.5)
Metastasis
Detected 12 (8.3)
Not detected 132 (91.7)
A
ERβ1
ERβ2
ERβ5
100 µm 100 µm
100 µm 100 µm
100 µm 100 µm
20 µm
20 µm
20 µm
BC
DEF
GHI
Figure 4 Typical IHC results of ERb immunostaining on TMAs.
TMAs with 144 specimens were immunostained with ERb1
(A–C), ERb2 (D–E), and ERb5 (G–I) antibodies/antisera. The
Allred scoring system (Allred scoreZsignal scoreCintensity
score) was used to grade the immunostaining signals. Typical
low Allred-scored sections (AllredZ0C1 for nuclear positivity;
AllredZ1C2t o1 C3 for cytoplasmic positivity) are shown in
A, D, and G. Higher Allred-scored sections (AllredZ3C5 for
both nuclear and cytoplasmic positivity) with strong nuclear and
cytoplasmic staining are shown in B, E, and H. C, F, and I
represent a magniﬁed view (!630) of a region (marked by a
rectangle) in B, E, and H respectively. Negative nuclear staining
in C, F, and I is marked by solid arrows.
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(PZ0.03; Fig. 6C) but not time to PF (PO0.05, data
not shown). In a combined analysis, patients whose
prostate specimen was positive for both nERb2 and
cERb5 had the shortest POM-free survival (P!0.01,
degrees of freedomZ3), i.e. worst clinical outcome
(Fig. 6D). Comparisons among pairs of groups
revealed that the group with a double positive for
nERb2 and cERb5 was signiﬁcantly different from the
group with a double negative (P!0.01) and with the
group with only nERb2 positive (PZ0.04).
Migration and invasion of PCa cells expressing
ERb isoforms
On the basis of the results from the TMA study
suggesting that both ERb2 and ERb5 could be the
markers for predicting time to POM, we further
investigated the role of these two isoforms in PCa
metastasis. We stably infected LacZ, ERb1, ERb2, and
ERb5 in PC3 cells with lentivirus, and measured cell
mobility and invasion ability of the cells expressing
different isoforms with wound-healing and invasion
assays respectively. Stable ectopic expression of each
ERb isoform in PC3 cells was conﬁrmed with
established real-time PCR assays (Leung et al. 2006).
A greater than 200-fold increase in ERb transcript was
detected in each stable-transfected cell line. In wound-
healing assays, PC3–ERb5 cells migrated signiﬁcantly
faster than the others after 24 h of wound introduction
(Fig. 7A). PC3–ERb2 cells migrated as fast as the
PC3–LacZ control cells, but PC3–ERb1 cells migrated
signiﬁcantly more slowly than control cells. In
invasion assays, the efﬁciency of invasion across the
matrix gel membrane of PC3–ERb2 and PC3–ERb5
cells was 64 and 42% respectively greater than that of
PC3–LacZ cells within 24 h (Fig. 7B). Interestingly,
ectopic expression of ERb1 in PC3 cells signiﬁcantly
reduced PCa cell invasiveness by 34% as compared
with PC3–LacZ.
Discussion
This is the ﬁrst study comparing the protein expression
of ERb1 with that of its isoforms ERb2 and ERb5i n
specimens from a cohort of patients with PCa (nZ144)
with long clinical follow-up. The immunohistochem-
ical expression of the three ERbs was analyzed in a set
of TMAs derived from the cohort using an ERb1-
speciﬁc antibody and two newly characterized antisera
for ERb2 and ERb5. nERb2 was found to be an
independent predictor for PF (adjORZ3.8, PZ0.04),
POM (adjORZ3.1, PZ0.02), and POM-free survival
(adjHRZ4.6, PZ0.02), whereas cERb5 was a pre-
dictor for POM-free survival in Kaplan–Meier
analysis. More importantly, patients positive for both
ERb isoforms (nERb2C and cERb5C) were found to
have the shortest POM-free survival (P!0.01). To
provide mechanistic insights into the clinical relevance
and prognostic signiﬁcance of both isoforms, we
ectopically expressed ERb isoforms in PC3 cells and
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Figure 5 Distribution of ERb isoforms in this prostate cancer
TMA. The immunopositivity signal of each isoform was graded
according to the Allred scoring system. Only an Allred score
greater than cutpoint (i.e. AllredO3) was considered positive.
The number of patients showing positive immunostaining
signals in different cellular compartments was determined and
analyzed. The correlations between two ERb isoform
expression were determined based on Spearman correlation
test. P!0.05 was considered to be statistically signiﬁcant. An
asterisk represents a speciﬁc group of patients with a higher
possibility of showing the worst clinical outcome.
Table 2 Spearman correlation S(r) between expression of estrogen receptor b1 (ERb1), ERb2, and ERb5 isoform
Nucleus Cytoplasm
n
a rP value rP value
ERb1 versus ERb2 134 0.45 !0.01 0.39 !0.01
ERb1 versus ERb5 134 0.10 0.23 0.38 !0.01
ERb2 versus ERb5 134 0.06 0.48 0.24 !0.01
P values testing rZ0.
aPatient numbers are !144 due to missing data.
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cell line increased the efﬁciency of cell migration (for
PC3–ERb5 cells) and cell invasiveness (for both
PC3–ERb2 and PC3–ERb5 cells) but did not alter
cell proliferation (unpublished data). Taken together,
these ﬁndings established that ERb2 and ERb5 are
strongly associated with PCa metastasis.
Estrogen has been shown to be involved in normal
and malignant functions of the prostate (Ho et al.
2006). Four decades ago, the oral estrogen diethyl-
stilbestrol was the treatment of choice for PCa
(Huggins & Hodges 2002). It was ultimately aban-
doned because of its serious cardiovascular and
thromboembolic toxicity (Hanash et al. 1970, Eisen
et al. 1975) and the emergence of gonadotropin
agonists/antagonists (Schally et al. 1983). However,
other forms of estrogen, including various ER selective
modulators, recently have emerged as effective and
economical therapies, largely because of clinical data
showing minimal hepatic toxicity of these agents if
they are administrated parentally via an intramuscular
or transdermal route (Ockrim et al. 2006). These
therapies also have signiﬁcant efﬁcacy in protecting
against osteoporotic fracture, hot ﬂashes, asthenia, and
cognitive dysfunction in patients with PCa (Ockrim
et al. 2006). With this renewed interest in using
estrogens as single or combination therapy for PCa, the
need to understand how ERs affect PCa is pressing.
Table 3 Descriptive statistics and results of regression analyses
Nuclear ERb2 (nZ136
a) Cytoplasmic ERb5 (nZ137
a)
Positive
b (%) Negative
b (%) P value Positive
b (%) Negative
b (%) P value
Clinicopathological features of PCa
Number of patients (n) 21 115 56 81
Age (years)
MeanGS.D. 59.5G5.9 62.3G6.1 0.06 62.3G6.1 61.7G6.3 0.58
Preoperative PSA (ng/ml)
Median (min, max) 5.0 (3.0, 20.1) 6.8 (0.05, 32.3) 0.03 6.6 (0.3, 32.3) 6.2 (0.05,
23.2)
0.71
Gleason score
!7 4 (19.1) 53 (46.1) 22 (39.3) 36 (44.4)
Z7 13 (61.9) 44 (38.3) 0.06 22 (39.3) 35 (43.2) 0.36
O7 4 (19.1) 18 (15.7) (dfZ2) 12 (21.4) 10 (12.4) (dfZ2)
Pathology stage
c
T2 19 (90.5) 89 (77.4) 43 (76.8) 66 (81.5)
T3 2 (9.5) 26 (22.6) 0.14 13 (23.2) 15 (18.5) 0.50
Surgical margins
Positive 7 (33.3) 50 (43.5) 25 (44.6) 32 (39.5)
Negative 14 (66.7) 65 (56.5) 0.47 31 (55.4) 49 (60.5) 0.60
PSA failure
Yes 14 (66.7) 39 (33.9) 22 (39.3) 31 (38.3)
No 7 (33.3) 76 (66.1) !0.01 34 (60.7) 50 (61.7) 0.90
Post-operative metastasis
Yes 5 (23.8) 7 (6.1) 8 (14.3) 4 (4.9)
No 16 (76.2) 108 (93.9) !0.01 48 (85.7) 77 (95.1) 0.06
Outcome adjOR adjHR P value adjOR adjHR P value
Adjusted odds ratio (adjOR
d) and hazard ratio (adjHR
d)
PSA failure 3.8 0.04 0.8 0.58
Time to PSA failure 1.8 0.10 0.8 0.47
Post-operative metastasis 3.1 0.02 3.1 0.09
Time to post-operative
metastasis
4.6 0.02 3.1 0.07
P values test i) differences in mean age and median preoperative PSA between positive and negative ERb isoforms; ii) differences in
Allred positivity rates among categories of Gleason score, pathology stage, and surgical margins.
aTable entries for count data indicate number of patients (%column total). Column totals are !144 due to missing data.
bCutpoint for positive: Allred score O3; cutpoint for negative: Allred score %3.
cNo stages 1 and 4 were detected.
dAdjOR measures the odds of a positive isoform from logistic regression, adjusted for age, Gleason score, and preoperative PSA;
AdjHR measures the hazard (or risk) of a positive isoform from a Cox proportional hazards model with the same adjustments.
Y-K Leung et al.: ERb isoforms and prostate cancer progression
www.endocrinology-journals.org 684Results from this study serve as the ﬁrst exploration to
open a new line of investigation.
The action of estrogen in human normal and
malignant prostatic tissue is believed to be mediated
partly by ERb because it is the predominant ER
subtype in the prostate epithelium (Kuiper et al. 1996,
Leav et al.2 0 0 1 ). However, the role of ERb in prostate
and breast cancers is still debatable, even after 10 years
of extensive research (Ho et al. 2006). Data from
different research groups conﬂict (Speirs et al. 2004,
Skliris et al. 2006), in part because of insufﬁcient
understanding of ERb isoforms that were discovered
relatively recently (Leung et al. 2006) and the lack of
antibodies to distinguish them in vitro and in clinical
specimens. Unlike breast cancer research, in which the
discovery of these molecules has stimulated new
research directions (Speirs & Walker 2007, Powell &
Xu 2008), similar developments in PCa research have
been limited. The use of N-terminal-speciﬁc ERb
antibodies in IHC experiments is always problematic
because they recognize all ERb isoforms, and mRNA
expression data clearly showed that each ERb isoform
has a unique, tissue- and cell type-speciﬁc expression
pattern (Leung et al. 2006). This study is the ﬁrst to
provide data at the protein level illustrating this
uniqueness in PCa. Our IHC staining revealed unique
tissue-/cell type- and cellular compartment-speciﬁc
distribution for each isoform in the normal and
malignant prostate.
The functions of each isoform in the normal prostate
epithelium are unclear. Thus, in this study, ERb1
positivity was not associated with PCa progression, but
the PC3 cell model suggested that ERb1 inhibits both
PCa cell migration and invasion, which is consistent
with the current belief that ERb is antiproliferative,
tumor suppressive (Morani et al. 2008) and impedes
epithelial–mesenchymal transition (Mak et al. 2010).
However,othershavesuggestedthatERbisinvolvedin
an aggressive PCa phenotype (Horvath et al. 2001,
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Figure 6 Evaluation of ERb isoforms as a predictor for time to
PSA failure and time to metastasis by the Kaplan–Meier (KM)
plot with the log-rank test. The Allred cutpoint (O3o r%3) for
each ERb isoform was used to determine ‘positive’ and
‘negative’ expression. (A) KM plot of nuclear ERb2 versus
recurrence/PSA-free survival (P!0.01). (B) KM plot of nuclear
ERb2 versus metastasis-free survival (P!0.01). (C) KM plot of
cytoplasmic ERb5 in metastasis-free survival (PZ0.03). (D) KM
plot of nuclear ERb2 and cytoplasmic ERb5 versus metastasis-
free survival (P!0.01). Patients were further stratiﬁed into four
groups according to status of ERb isoform expression: i) both
nuclear ERb2 and cytoplasmic ERb5 positive (nZ9); ii) nuclear
ERb2 positive and cytoplasmic ERb5 negative (nZ12); iii)
nuclear ERb2 negative and cytoplasmic ERb5 positive (nZ46);
and iv) both nuclear ERb2 and cytoplasmic ERb5 negative
(nZ68). P!0.05 was considered to be statistically signiﬁcant.
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discrepancy will be resolved in the future by including
ERb isoforms during data analysis. In this TMA study,
ERb2, the most commonly expressed isoform (O80%)
in PCa cells, is primarily cytoplasmic, and its nuclear
positivity correlates with PF, POM, and a shorter time
to POM. These results are in agreement with a study
with a smaller cohort analyzed with different clinical
outcomes (Fujimura et al. 2001). However, this study
was the ﬁrst to investigate ERb5 and its prognostic
value in PCa. Both ERb2 and ERb5 elevated PCa cell
invasion, but only the cells expressing ERb5 migrated
more rapidly. This suggests that ERb2 and ERb5 could
regulate different tumor metastasis pathways in PCa
cells, perhaps explaining why co-existence of ERb2
and ERb5 in PCa tissue could predict the worst clinical
outcome, probably due to synergistic actions of ERb2
and ERb5 in PCa progression. Through the use of
isoform-speciﬁc antibodies, we have gained new
insights into the prognostic values of ERb isoforms
that will undoubtedly continue to increase our under-
standingofERbsinthedevelopmentandprogressionof
PCa. The utility of ERb2 and ERb5 as PCa prognostic
markers is obviously worthy of further investigation.
Both isoforms have been found in various tissues
(Pedersen et al. 2001, Scobie et al.2 0 0 2 , Poola 2003,
Cammarata et al. 2005, Wong et al. 2005), including
the prostate (Leung et al. 2006). The functions of these
isoforms are not yet clear, but they are known to be
involved in ERa (Peng et al. 2003, Poola et al. 2005)
and ERb1 signaling (Leung et al. 2006). At the
molecular level, either ERb2o rE Rb5 by itself does not
transactivate ERE-driven promoter but when hetero-
dimerized with ERb1 can alter its transactivation
activity (Leung et al. 2006). The roles of ERb2 and
ERb5 in cancer were not studied until recently. Their
nuclear expression in breast cancer tissue was
signiﬁcantly correlated with better overall survival
(Shaaban et al. 2008), a ﬁnding that differs from our
data showing a signiﬁcant correlation between
ERb2/ERb5 positivity in PCa cells and poor POM-
free survival. This discrepancy suggests a fundamental
difference in the role played by estrogens/estrogen
signaling in the pathogenesis of PCa versus that of
breast cancer, which has introduced an intriguing
question regarding the clinical management of
these cancers.
We recognize that our cohort is small (144 patients)
compared with that of the breast cancer study (Shaaban
et al. 2008) and thus includes relatively few patients
with PF (nZ54; R2 n g / m l )a n dP O M( nZ12).
However, the possibility of using ERb2 and ERb5
for PCa prognosis shows great promise, partly because
of the long lead-time before postoperative PF (6.2
years) and time to POM (8.6 years). Therefore, the
conﬁrmation of ERb2, in conjunction ERb5 or other
established markers, as an independent prognostic
marker in future cohort studies, could help to identify
candidates for clinical trials of new interventions
designed to curb PCa progression based on information
gained at the time of radical prostatectomy from IHC
analysis for ERbs. Moreover, more active surveillance
and/or adjuvant therapies, such as external beam
radiotherapy and ADTs (Michaelson et al. 2008,
Wirth et al. 2008), may be indicated for the subset of
patients at higher risk for metastases because of their
positivity for ERb2 and ERb5.
Mechanistic studies aimed at elucidating the
biological roles of ERbs require relevant cell model
systems. Cammarata et al. (2005) were the ﬁrst to
report different subcellular localizations of ERb iso-
forms in breast cancer cells. In a PCa cell line (PC3),
ERb1 resides mostly in the nucleus. Although very few
ERb1 molecules were detected in cytoplasm, they were
not localized in the mitochondria in this PCa cell line, a
ﬁnding different from other published cell data (Chen
et al. 2004). Both ERb2 and ERb5 were localized in
both cytoplasmic and nuclear compartments in PC3
cells. It is not clear whether such unique patterns of
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Figure 7 Tumor metastasis of PC3 expressing ERb isoforms.
(A) Results of wound-healing assay. Migration distance of PC3
expressing LacZ (as a control), ERb1, ERb2, and ERb5 was
recorded and calculated after 24 h of wound introduction.
Experiments were carried out in triplicate and were repeated
with three independent sets. Student’s t-test was used to
compare the mean distance migrated of each ERb isoform-
expressing cell line versus LacZ control cells (averageGS.E.M.,
*P!0.05). (B) Results of Matrigel-based invasion assay. Fixed
number (5!10
4) of cells was set up in a 24-well plate according
to the manufacturer’s recommendation. The cells that crossed
the matrigel membrane were stained and counted under a
microscope. Cell numbers were normalized by the MTS
method. The fold invasiveness was calculated relative to the
number of cells invaded in LacZ control. Experiments were
carried out in triplicate and were repeated with three
independent sets. Student’s t-test was used to compare the fold
invasiveness of each cell line versus LacZ control cells
(averageGS.E.M., *P!0.05).
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are related to their metastasis-promoting functions or
simply to differential protein trafﬁcking and/or proces-
sing. Those are the questions worthy of further
investigation. As a caveat, it is almost certain that
there are no perfect cell model systems that could fully
recapitulate the in vivo situation, whereby epithelial
cells are surrounded by different types of stromal
cells in a three-dimensional architecture. Thus,
interpretations of data from cell model systems
would best be supported by parallel correlative studies
of human tissues.
In conclusion, in a group of PCa patients with
relatively long follow-up, our data demonstrate that
expression of ERb2 in the nucleus of PCa cells is an
independent prognostic marker of PF, POM, and time
to POM, and cERb5 positivity predicts shorter POM-
free survival. Additionally, the expression of both
nERb2 and cERb5 identiﬁed a group of patients with
the worst clinical outcome. Finally, forced expression
of ERb2o rE R b5 in PC3 cells uncovered that these
isoforms have metastasis-promoting action, supporting
our IHC ﬁndings. Given the long duration of time to
PF/POM, prognostic markers such as these should help
in stratifying patients in clinical trials and in devising
more effective customized therapies for advanced PCa.
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